Drug
Momelotinib clinical trials
Also written CYT387 and GS-0387.
Keep track of what changes. Save the momelotinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 4
Sierra Oncology LLC - a GSK company (12) · GlaxoSmithKline (4) · SWOG Cancer Research Network (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
Often tested with
Tested in the same studies.
Ruxolitinib (1) · Gilteritinib (1) · Luspatercept (1) · Erlotinib (1) · Trametinib (1)
Studies
Open first, then newest update. How each study uses momelotinib is read from its arms, and is right about nine times in ten.
Testing it · 20
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06235801Written as Momelotinib
- Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell CountsNot yet recruitingPhase 4SWOG Cancer Research NetworkNCT07498205Written as Momelotinib
- A Study of Momelotinib in Participants With Low-risk Myelodysplastic SyndromeRecruitingPhase 2GlaxoSmithKlineNCT06847867Written as Momelotinib
- A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeNot yet recruitingPhase 2/3GlaxoSmithKlineNCT07569081Written as Momelotinib
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisRecruitingPhase 2GlaxoSmithKlineNCT06517875Written as Momelotinib
- Momelotinib During and After HCT in MyelofibrosisRecruitingPhase 1Massachusetts General HospitalNCT07104799Written as Momelotinib
- Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaRecruitingEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07071155Written as Momelotinib
- Extended Access of Momelotinib in Adults With MyelofibrosisActive, not recruitingPhase 2GlaxoSmithKlineNCT03441113Written as MMB
- A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedPhase 3Sierra Oncology LLC - a GSK companyNCT04173494Written as Momelotinib
- Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaTerminatedPhase 3Sierra Oncology LLC - a GSK companyNCT02101021Written as Momelotinib
- Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompletedPhase 2Sierra Oncology LLC - a GSK companyNCT02124746Written as Momelotinib
- Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)CompletedPhase 2Sierra Oncology LLC - a GSK companyNCT02515630Written as MMB
- Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompletedPhase 3Sierra Oncology LLC - a GSK companyNCT02101268Written as Momelotinib
- Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompletedPhase 3Sierra Oncology LLC - a GSK companyNCT01969838Written as Momelotinib
- Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedPhase 2Sierra Oncology LLC - a GSK companyNCT01998828Written as Momelotinib
- Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompletedPhase 1/2Sierra Oncology LLC - a GSK companyNCT01423058Written as Momelotinib
- Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedPhase 2Sierra Oncology LLC - a GSK companyNCT01236638Written as Momelotinib
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedPhase 1/2Sierra Oncology LLC - a GSK companyNCT00935987Written as CYT387
- Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 1Sierra Oncology LLC - a GSK companyNCT02206763Written as Momelotinib (MMB)
- Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseTerminatedPhase 1Sierra Oncology LLC - a GSK companyNCT02258607Written as Momelotinib (MMB)
Given in every arm · 5 — momelotinib is usual care beside what is tested
- A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisRecruitingPhase 1/2Sumitomo Pharma America, Inc.NCT04176198Written as Momelotinib
- A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative NeoplasmsRecruitingPhase 1Janssen Research & Development, LLCNCT06150157Written as Momelotinib
- Revumenib in Patients With MyelofibrosisNot yet recruitingPhase 1/2John MascarenhasNCT07734077Written as Momelotinib
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingPhase 2Karyopharm Therapeutics IncNCT05980806Written as Momelotinib
- Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal AdenocarcinomaTerminatedPhase 1Sierra Oncology LLC - a GSK companyNCT02244489Written as Momelotinib (MMB)
Codes
What other systems call momelotinib · ClinicalTrials.gg INT005548
- MeSH (NLM) C546012momelotinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6O01GMS00PMOMELOTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q252602momelotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88311MomelotinibOne source FDA
- DrugBank DB11763One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546012 | momelotinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6O01GMS00P | MOMELOTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q252602 | momelotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88311 | Momelotinib | One source FDA |
| DrugBank | DB11763 | — | One source Wikidata |
Also registered as momelotinib dihydrochloride (UNII RBH995N496) and momelotinib dihydrochloride monohydrate (UNII LDX8893L5D).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.